Byung-Gu Min

Title: Byung-Gu Min: Innovator in Pharmaceutical Development

Introduction

Byung-Gu Min is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations that enhance patient convenience and minimize side effects.

Latest Patents

One of his key patents is for a slow-release cilostazol tablet that boasts an improved elution rate and minimal side effects. This innovative tablet includes cilostazol as a pharmacologically active component, which is effective in suppressing blood platelet aggregation and promoting vascular relaxation by inhibiting phosphodiesterase types. The slow-release formulation allows for once-daily dosing, improving the convenience of drug use. Additionally, it minimizes headaches, a common side effect associated with traditional cilostazol preparations, particularly in women, the elderly, and children. The tablet also exhibits a stable elution pattern, unaffected by changes in pH in the stomach and intestines, thanks to a mixture of hydroxypropyl methylcellulose and a carbomer as a release-controlling polymer.

Career Highlights

Byung-Gu Min is currently associated with Korea United Pharm, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on enhancing drug formulations to improve patient outcomes and adherence to medication regimens.

Collaborations

He has collaborated with notable colleagues, including Youn-Woong Choi and Sang-Min Cho, to advance research and development in their field.

Conclusion

Byung-Gu Min's contributions to pharmaceutical innovations, particularly through his slow-release cilostazol tablet, highlight his commitment to improving patient care and medication efficacy. His work exemplifies the importance of innovation in the healthcare industry.